UPDATE ON THE MEDICAL TREATMENT OF ENDOMETRIOSIS

D A Minjarez, Debra A. Minjarez, Minjarez DA, Schlaff WD, W D Schlaff, William D. Schlaff
Obstetrics and Gynecology Clinics of North America · 2000 · vol. 27(3) , pp. 641–651 · doi:10.1016/s0889-8545(05)70161-3 · PMID:10958009 · W1983818442
review OA: closed CC0 ⤵ 19 in-corpus citations
View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-07 ⓘ

This review discusses current medical treatments for endometriosis, focusing on hormonal therapies and pain management strategies.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

The treatment of women with endometriosis can be a challenge. Therapeutic strategies must be tailored to the individual symptoms, age, and desire for fertility. Medical therapy continues to be based on endocrine treatment, such as oral contraceptives, progestins, danazol, and GnRH agonists. Unfortunately, recurrence rates are high after discontinuation of therapy. Recent clinical research on GnRH analogues plus add-back therapy has produced favorable results. Long-term treatment of patients using this approach has successfully reduced pain while minimizing symptoms of hypoestrogenism and adverse metabolic effects, such as loss of bone mineral density. Currently, GnRH analogues given with add-back therapy seems to be the most effective long-term approach to the treatment of symptomatic endometriosis. In the future, other modalities, such as medicated vaginal rings, inhibitors of steroidogenic enzymes, and GnRH antagonists, will most likely be options.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Contraceptives, Oral Contraceptives, Oral Contraceptives, Oral Danazol Danazol Danazol Endometriosis Endometriosis Endometriosis Estrogen Antagonists Estrogen Antagonists Estrogen Antagonists Female Gonadotropin-Releasing Hormone Gonadotropin-Releasing Hormone Humans Progestins Progestins Progestins

Citation neighborhood

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. [ expand to 2 hops ] — adds papers reached through this work's immediate citers/citees. Heavier; up to 60 extra dots.

References (70)

Cited by (19)

Source provenance

europepmc
last seen: 2026-09-21T06:08:07.822426+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-05-13T22:13:36.046895+00:00
License: CC0 · commercial use OK